2223 GMT - Pathology services provider Healius's target of a high-single-digit Ebit margin by FY 2027 looks ambitious to Jefferies. Healius expects to reach this goal through a mix of revenue and cost initiatives. However, analyst David Stanton forecasts Healius achieving a 4.4% margin in FY 2028. "Growth in Ebit margin is not expected to be linear in the timeframe--we believe it is likely to be back-ended," Jefferies says. "We estimate that low-end to high-end targets imply FY 2028 Pathology Ebit margins of 7.0% to 8.6%." (david.winning@wsj.com; @dwinningWSJ)
(END) Dow Jones Newswires
March 27, 2025 18:23 ET (22:23 GMT)
Copyright (c) 2025 Dow Jones & Company, Inc.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.